Sarcoma


Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation (March 16, 2017)

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application... Continue Reading

Chemotherapy Before Surgery Improves Treatment of Sarcoma (November 7, 2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival.... Continue Reading

FDA Approves Lartruvo in Combination with Doxorubicin for Soft Tissue Sarcoma (November 2, 2016)

It was announced that the U.S. Food and Drug Administration (FDA) has granted approval of Lartruvo™ (olaratumab), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma... Continue Reading

Radiation Improves Survival in Older Patients with Soft Tissue Sarcomas (April 25, 2016)

UC Davis researchers have shown that radiation therapy following surgery benefits older patients more than their younger counterparts, a surprising finding that could change the way some patients are treated... Continue Reading

CancerConnect Announces Recent Updates to the Sarcoma Information Center (April 4, 2016)

As of April 1, 2016 CancerConnect has completed our most recent updates to our Sarcoma Information Center.  There have recently been several significant advances in the treatment of soft tissue sarcoma... Continue Reading

Stage IV and Recurrent Soft Tissue Sarcoma: Limbs, Outer Trunk, Head, or Neck (March 17, 2016)

Overview Patients diagnosed with stage IV soft tissue sarcoma (STS) have a cancer of any size or grade that has spread to distant parts of the body such as the lungs. Sarcoma Centers & Second Opinions Because... Continue Reading

Stage II and III Soft Tissue Sarcoma: Limbs, Outer Trunk, Head or Neck (March 17, 2016)

Patients diagnosed with stage II or III soft tissue sarcoma (STS) are treated differently depending on the size of the primary tumor, the tumor grade, and whether or not the sarcoma has spread to the local... Continue Reading

Stage I Soft Tissue Sarcoma: Limbs, Outer Trunk, Head or Neck (March 17, 2016)

Overview Patients diagnosed with stage I soft tissue sarcoma (STS) have a low grade or unknown grade cancer that can be superficial or deep and does not involve any lymph nodes. Stage I STS is further... Continue Reading

Sarcoma Centers (March 17, 2016)

Because sarcomas are uncommon it is important to find physicians who have experience with this disease. In the United States there are several locations that have physicians and teams dedicated to advancing... Continue Reading

Halaven Approved for Liposarcoma (February 4, 2016)

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated... Continue Reading

Yondelis® Approved for Treatment of Soft Tissue Sarcoma (November 2, 2015)

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The... Continue Reading

Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma (October 20, 2015)

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or progressed... Continue Reading

Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven® (June 11, 2015)

Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of the American Society of... Continue Reading

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma (February 4, 2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including... Continue Reading

OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

Torisel Improves Event-Free Survival in Rhabdomyosarcoma Patients (June 27, 2014)

In a study presented at the 2014 American Society of Clinical Oncology® meeting in Chicago, researchers reported that Torisel® (temsirolimus) added to a chemotherapy regimen improved event-free survival... Continue Reading

Marriage May Have a Protective Effect for Cancer Patients (December 17, 2013)

Social support may have a significant impact on cancer detection, treatment, and survival, according to the results of a study published in the Journal of Clinical Oncology. The study showed that married... Continue Reading

Strategies to Improve Treatment (December 16, 2013)

The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. Clinical trials are studies that evaluate the effectiveness of new drugs... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS